Shots: The company has reported the first patient dosing in the P-I CALOSOMA study assessing the safety, tolerability, PK/PD of GLPG3970 single & multiple ascending doses in up to 52 […]readmore
Tags : Galapagos
Shots: The CHMP’s positive opinion is based on P-III FINCH and P-II DARWIN programs that included 4,544 RA patient-years of experience with filgotinib. All three FINCH trials involve a broad […]readmore
Shots: The P-IIb/III SELECTION study involves assessing of filgotinib (200/ 100mg) vs PBO in 1,348 biologic-naïve & biologic-experienced patients in a ratio (2:2:1) with mod. to sev. UC. The SELECTION […]readmore
The 2020 JP Morgan Healthcare Conference was loaded with insights from key pharma companies. An analysis of events and catalysts that were announced or updated at the conference these days […]readmore
Shots: Fibrocor to receive upfront, option exercise fee, milestones and royalties on sales of the product. Galapagos to receive an exclusive option to in-license up to 4 targets, out of […]readmore
1. Medtronic Reports MHLW’s Shonin Approval and Launches Valiant Navion Thoracic Stent Graft System in Japan Published: Oct 31, 2019 | Tags: Medtronic, Reports, MHLW, Shonin Approval, Launches, Valiant Navion Thoracic […]readmore
Shots: The discontinuation of a clinical program is based on an interim analysis for futility in P-II IGUANA study which demonstrated low probability to meet 1EPs i.e, the percentage change […]readmore
Profound Medical’s TULSA-PRO Receives the US FDA’s 510(k) Clearance for Ablation of Prostate Tissue Published: Aug 16, 2019 | Tags: 510(k), Ablation, Clearance, Profound Medical, Prostate Tissue, Receives, TULSA-PRO, The US […]readmore
Shots: The MAA is based on P-III FINCH studies assessing Filgotinib (qd) in patients with RA resulted in improvements in clinical signs & symptoms, low disease activity and remission, inhibition […]readmore
Shots: Galapagos to receive $3.95B upfront and $1.1B equity investment. Gilead to get rights of Galapagos’ GLPG1690 for IPF, option rights of GLPG1972 for OA in the US and option […]readmore